Jessica Teh
4PUBLICATIONS
50CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|May 31, 2024
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.Sheryl M Gough, John J Flanagan, Jessica Teh
|Aug 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Marco H Hofmann, Michael Gmachl, Juergen Ramharter
|Jul 15, 2020
Activation of CD8<sup>+</sup> T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors.Jessica L F Teh, Dan A Erkes, Phil F Cheng
|May 21, 2020
Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.Jessica L F Teh, Timothy J Purwin, Anna Han
Pageof 1
Frequent Collaborators
2 joint publications
Andrew E Aplin
1 joint publications
Timothy J Purwin
1 joint publications
Anna Han
1 joint publications
Vivian Chua
1 joint publications
Takami Sato
1 joint publications
Michael A Davies
1 joint publications
Phil F Cheng
1 joint publications
Nicole A Wilski
1 joint publications
Xiaowei Xu
1 joint publications
Marco H Hofmann
